Our laboratory is focused on the discovery of new classes of anticancer agents and delineation of the mechanism of their antitumor actions. Further, we strive to understand the mechanistic basis of ovarian cancer markers and ovarian cancer stem cells. Our efforts have resulted in the discovery of the first non-hypercalcemic vitamin-D derived anticancer agents MT19c and PT19c. These agents including variety of other new structural classes of anticancer agents discovered by us have shown promising safety and antitumor efficacy profiles in animal models of epithelial ovarian cancer, endometrial cancer, neuroblastoma and medulloblastoma. In our laboratory, genome-wide mRNA analysis and copy number changes as tumors evolved over the time have revealed key drivers of ovarian cancer and at present, the efficacy of small molecules or phosphorothioates (PTOs) that inhibit the biological functions of these drivers is being studied. Our laboratory is also developing and evaluating new classes of insulin secretagogues for the treatment of type-II diabetes in humans.